Successful Immune Tolerance Induction to Enzyme Replacement Therapy in CRIM-negative Infantile Pompe Disease

Overview

Journal Genet Med

Publisher Elsevier

Specialty Genetics

Date 2012 Jan 13

PMID 22237443

Citations 113

Authors

Yoav H Messinger

Nancy J Mendelsohn

William Rhead

David Dimmock

Eli Hershkovitz

Michael Champion

Simon A Jones

Rebecca Olson

Amy White

Cara Wells

Deeksha Bali

Laura E Case

Sarah P Young

Amy S Rosenberg

Priya S Kishnani

Affiliations

Soon will be listed here.

Abstract

Purpose: Infantile Pompe disease resulting from a deficiency of lysosomal acid α-glucosidase (GAA) requires enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly. We describe successful tolerance induction in CRIM-negative patients.

Methods: Two CRIM-negative patients with preexisting anti-GAA antibodies were treated therapeutically with rituximab, methotrexate, and gammaglobulins. Two additional CRIM-negative patients were treated prophylactically with a short course of rituximab and methotrexate, in parallel with initiating rhGAA.

Results: In both patients treated therapeutically, anti-rhGAA was eliminated after 3 and 19 months. All four patients are immune tolerant to rhGAA, off immune therapy, showing B-cell recovery while continuing to receive ERT at ages 36 and 56 months (therapeutic) and 18 and 35 months (prophylactic). All patients show clinical response to ERT, in stark contrast to the rapid deterioration of their nontolerized CRIM-negative counterparts.

Conclusion: The combination of rituximab with methotrexate ± intravenous gammaglobulins (IVIG) is an option for tolerance induction of CRIM-negative Pompe to ERT when instituted in the naïve setting or following antibody development. It should be considered in other conditions in which antibody response to the therapeutic protein elicits robust antibody response that interferes with product efficacy.

Citing Articles

Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.

Jarvi N, Patel M, Shetty K, Nguyen N, Grasperge B, Mager D Front Immunol. 2024; 15():1496169.

PMID: 39720710 PMC: 11666448. DOI: 10.3389/fimmu.2024.1496169.

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.

Carter P, Quarmby V Nat Rev Drug Discov. 2024; 23(12):898-913.

PMID: 39424922 DOI: 10.1038/s41573-024-01051-x.

Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation.

Fares A, Desai A, Case L, Sharon C, Klinepeter A, Kirby A Mol Genet Metab Rep. 2024; 41:101141.

PMID: 39314994 PMC: 11419802. DOI: 10.1016/j.ymgmr.2024.101141.

Mutation Spectrum of Gene in Pompe Disease: Current Knowledge and Results of an Italian Study.

Moschetti M, Lo Curto A, Giacomarra M, Francofonte D, Zizzo C, Messina E Int J Mol Sci. 2024; 25(17).

PMID: 39273088 PMC: 11394944. DOI: 10.3390/ijms25179139.

Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.

Chen H, Hsu R, Fang C, Desai A, Lee N, Hwu W Front Immunol. 2024; 15:1336599.

PMID: 38715621 PMC: 11074348. DOI: 10.3389/fimmu.2024.1336599.

References

Kishnani P, Howell R . Pompe disease in infants and children. J Pediatr. 2004; 144(5 Suppl):S35-43. DOI: 10.1016/j.jpeds.2004.01.053. View

Mendelsohn N, Messinger Y, Rosenberg A, Kishnani P . Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 2009; 360(2):194-5. DOI: 10.1056/NEJMc0806809. View

Wraith J, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y . Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007; 120(1):e37-46. DOI: 10.1542/peds.2006-2156. View

Kishnani P, Goldenberg P, DeArmey S, Heller J, Benjamin D, Young S . Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2009; 99(1):26-33. PMC: 3721340. DOI: 10.1016/j.ymgme.2009.08.003. View

Kakkis E, Muenzer J, Tiller G, Waber L, Belmont J, Passage M . Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001; 344(3):182-8. DOI: 10.1056/NEJM200101183440304. View

Desnick R . Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis. 2004; 27(3):385-410. DOI: 10.1023/B:BOLI.0000031101.12838.c6. View

Brooks D . Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab. 1999; 68(2):268-75. DOI: 10.1006/mgme.1999.2894. View

Stasi R, Cooper N, Del Poeta G, Stipa E, Evangelista M, Abruzzese E . Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008; 112(4):1147-50. DOI: 10.1182/blood-2007-12-129262. View

Biss T, Velangi M, Hanley J . Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature. Haemophilia. 2006; 12(3):280-4. DOI: 10.1111/j.1365-2516.2006.01212.x. View

10.

Nimmerjahn F, Ravetch J . Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008; 26:513-33. DOI: 10.1146/annurev.immunol.26.021607.090232. View

11.

Amalfitano A, Bengur A, Morse R, Majure J, Case L, Veerling D . Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001; 3(2):132-8. DOI: 10.109700125817-200103000-00007. View

12.

Warrier I, Ewenstein B, Koerper M, Shapiro A, Key N, DiMichele D . Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997; 19(1):23-7. DOI: 10.1097/00043426-199701000-00003. View

13.

Rohrbach M, Klein A, Kohli-Wiesner A, Veraguth D, Scheer I, Balmer C . CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis. 2010; 33(6):751-7. DOI: 10.1007/s10545-010-9209-0. View

14.

Kishnani P, Nicolino M, Voit T, Rogers R, Chun-Hui Tsai A, Waterson J . Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006; 149(1):89-97. PMC: 2692727. DOI: 10.1016/j.jpeds.2006.02.035. View

15.

Smith K, Jones R, Burns S, Jayne D . Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006; 54(9):2970-82. DOI: 10.1002/art.22046. View

16.

Hay C, Recht M, Carcao M, Reipert B . Current and future approaches to inhibitor management and aversion. Semin Thromb Hemost. 2006; 32 Suppl 2:15-21. DOI: 10.1055/s-2006-946910. View

17.

Kishnani P, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu W . Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2006; 68(2):99-109. DOI: 10.1212/01.wnl.0000251268.41188.04. View

18.

Anthony R, Wermeling F, Karlsson M, Ravetch J . Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008; 105(50):19571-8. PMC: 2604916. DOI: 10.1073/pnas.0810163105. View

19.

Banugaria S, Prater S, Ng Y, Kobori J, Finkel R, Ladda R . The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011; 13(8):729-36. PMC: 3954622. DOI: 10.1097/GIM.0b013e3182174703. View

20.

Linthorst G, Hollak C, Donker-Koopman W, Strijland A, Aerts J . Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004; 66(4):1589-95. DOI: 10.1111/j.1523-1755.2004.00924.x. View